Intermediate to advanced hepatocellular carcinoma
Conditions
Interventions
Case series:apatinib
Sponsors
The First Affiliated Hospital of University of Science and Technology of China
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients with hepatocellular carcinoma diagnosed clinically or histopathologically; 2. Aged >=18 years male or female; 3. Patients with BCLC stage B or C who cannot tolerate or refuse surgery (Schedule 1); 4. Child-pugh rating of liver function: Grade A or better Grade B (7 points); 5. ECOG score 0-2; 6. Patients who researchers believe could benefit
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating female patients; 2. Patients with apatinib or TACE treatment contraindications (such as: abnormal coagulation function, severe abnormality of liver, kidney and lung function, active bleeding, gastrointestinal ulcer, intestinal perforation or ileus, poorly controlled hypertension, etc.); 3. According to the judgment of the researcher, it is not suitable for the patients participating in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Countries
China
Contacts
Public ContactWeifu Lv
The First Affiliated Hospital of University of Science and Technology of China
Outcome results
None listed